Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 11/2010

01-09-2010 | Original Article

A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis

Authors: Anna Rita Giardina, Angelo Ferrante, Francesco Ciccia, Rosalia Impastato, Maria Concetta Miceli, Alfonso Principato, Giovanni Triolo

Published in: Rheumatology International | Issue 11/2010

Login to get access

Abstract

The signs and symptoms of ankylosing spondylitis (AS) respond inadequately to nonsteroidal antiinflammatory drugs, corticosteroids, and disease modifying antirheumatic drugs in quite a number of patients. Tumor necrosis factor inhibitors have demonstrated to be of value in reducing AS disease activity in clinical trials. The efficacy and safety of both etanercept and infliximab in patients with ankylosing spondylitis were compared in a 2-year open label randomised study. Our results are consistent with a significant more rapid clinical improvement in the infliximab treated group. Treatment with both etanercept and infliximab at the end of the study was effective, safe, and well tolerated.
Literature
1.
Khan MA (2002) Update on spondyloarthropathies. Ann Intern Med 135:896–907
2.
Zochling J, van der Heijde D, Dougados M et al (2006) Current evidence for the management of ankylosing spondylitis: systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis 65:423–432CrossRefPubMed
3.
Rudwaleit M, Hohler T (2001) Cytokine gene polymorphisms relevant for the spondyloarthropathies. Curr Opin Rheumatol 13:250–254CrossRefPubMed
4.
Davis JC, van der Heijde DM, Braun J et al (2008) Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis 67:346–352CrossRefPubMed
5.
Brandt J, Khariouzov A, Listing J, Haibel H et al (2003) Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 48:1667–1675CrossRefPubMed
6.
Davis JC, van der Heijde DM, Braun J et al (2003) Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis. Arthritis Rheum 48:3230–3236CrossRefPubMed
7.
Calin A, Dijkmans BAC, Emery P et al (2004) Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 63:1594–1600CrossRefPubMed
8.
Brandt J, Listing J, Haibel H et al (2005) Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. Rheumatology 44:342–348CrossRefPubMed
9.
Braun J, Brandt J, Listing J et al (2002) Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359:1187–1193CrossRefPubMed
10.
Braun J, Brandt J, Listing J et al (2005) Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis 64:229–234CrossRefPubMed
11.
van der Heijde D, Dijkmans B, Geusens P et al (2005) Efficacy and safety of infliximab in patients with ankylosing spondylitis. Arthritis Rheum 52:582–591CrossRefPubMed
12.
Marzo-Ortega H, McGonagle D, Jarrett S et al (2005) Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study. Ann Rheum Dis 64:1568–1575CrossRefPubMed
13.
Braun J, Brandt J, Listing J et al (2003) Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Arthritis Rheum 48:2224–2233CrossRefPubMed
14.
Braun J, Landewé R, Hermann KGA et al (2006) Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab. Results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum 54:1646–1652CrossRefPubMed
15.
Hochberg MC, Lebwohl MG, Plevy SE, Hobbs KF, Yocum DE (2005) The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum 34:819–836CrossRefPubMed
16.
Van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 27:361–368CrossRefPubMed
17.
Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M (2001) Ankylosing Spondylitis Assessment Group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 44:1876–1886CrossRefPubMed
18.
Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A (1994) Defining spinal mobility in ankylosing spondylitis (AS): the Bath AS Metrology Index. J Rheumatol 21:1694–1698PubMed
19.
Fernández-Sueiro JL, Willisch A, Pértega-Díaz S et al (2009) Evaluation of ankylosing spondylitis spinal mobility measurements in the assessment of spinal involvement in psoriatic arthritis. Arthritis Rheum 61(3):386–392CrossRefPubMed
Metadata
Title
A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis
Authors
Anna Rita Giardina
Angelo Ferrante
Francesco Ciccia
Rosalia Impastato
Maria Concetta Miceli
Alfonso Principato
Giovanni Triolo
Publication date
01-09-2010
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 11/2010
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-009-1157-3

Other articles of this Issue 11/2010

Rheumatology International 11/2010 Go to the issue

Case Report

Coexisting relapsing polychondritis and sarcoidosis: an unusual association

Letter to the Editor

Acute acalculous cholecystitis in systemic sclerosis

Original Article

Ultrasonographic assessment of clinically diagnosed trigger fingers

Case Report

Lupus myocarditis: marked improvement in cardiac function after intravenous immunoglobulin therapy

Original Article

Diagnostic value of synovial fluid anti-cyclic citrullinated peptide antibody for rheumatoid arthritis

Original Article

Systemic, secondary and infectious causes for cerebral vasculitis: clinical experience with 16 new European cases
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits